BRCA2 and neoplasm: Recent clinical trials of molecular-based precision medicine on patients and their families (i.e., probands and relatives) suffering from hereditary tumors have yielded encouraging evidence for utilizing molecular-based knowledge of HR not only against tumor development associated with BRCA1 and BRCA2, but also for other HR-related gene variants carrying moderate or low tumor development risks [5,6].